Literature DB >> 36184729

The Roles and Mechanisms of TRAT1 in the Progression of Non-Small Cell Lung Cancer.

Qiang Guo1, Si-Hua Wang1, Yan-Mei Ji2, Song Tong1, Dan Li3, Xiang-Chao Ding4, Chuang-Yan Wu5.   

Abstract

OBJECTIVE: T cell receptor-associated transmembrane adaptor 1 (TRAT1) is one of the hub genes regulating T cell receptors (TCRs). Herein, the roles of TRAT1 in the prognosis and immune microenvironment of non-small cell lung cancer (NSCLC) were investigated.
METHODS: The expression and prognosis values of TRAT1 in NSCLC, and the relationship between TRAT1 expression levels and cancer immune cell infiltration was identified via the TIMER, UALCAN, TISIDB, and other databases. The mechanism of TRAT1 in NSCLC was analyzed using gene set enrichment analysis (GSEA).
RESULTS: The expression level of TRAT1 was decreased in NSCLC tissues. Low TRAT1 expression was associated with shorter overall survival of patients with NSCLC and was related to gender, smoking, and tumor grade. TRAT1 was involved in regulating immune response, TCR signaling pathway, PI3K/AKT, and other processes. TRAT1 expression levels were positively correlated with immune cell infiltration in NSCLC.
CONCLUSION: Down-regulation of TRAT1 expression was associated with an unfavorable prognosis and immune infiltration of NSCLC.
© 2022. Huazhong University of Science and Technology.

Entities:  

Keywords:  T cell receptor-associated transmembrane adaptor 1; T cell receptors; immune infiltration; non-small cell lung cancer; prognosis

Year:  2022        PMID: 36184729     DOI: 10.1007/s11596-022-2625-1

Source DB:  PubMed          Journal:  Curr Med Sci        ISSN: 2523-899X


  2 in total

1.  RNF113A promotes the proliferation, migration and invasion, and is associated with a poor prognosis of esophageal squamous cell carcinoma.

Authors:  Lei Wang; Zhichao Hou; Ayshamgul Hasim; Abulajiang Abuduerheman; Haiping Zhang; Madiniyat Niyaz; Idiris Awut; Halmurat Upur; Ilyar Sheyhidin
Journal:  Int J Oncol       Date:  2018-01-24       Impact factor: 5.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.